AstraZeneca (AZN) Acquires Neuroscience Assets from Mazzachusetts-Based Link Medicine

July 12, 2012 8:03 AM EDT Send to a Friend
AstraZeneca (NYSE: AZN) has acquired a portfolio of neuroscience assets from Link Medicine Corporation, a privately held biopharmaceutical company based in Massachusetts, USA. Link Medicine has focused its research and development efforts in the field of autophagy, an intracellular process that clears and recycles misfolded proteins and has been developing potential new treatments for a range of neurodegenerative diseases.

AstraZeneca acquired multiple small molecule assets in clinical and preclinical stage that target the enzyme farnesyltransferase and modulate autophagy. Autophagy is an emerging area of research that can be applied to a range of neurodegenerative diseases, including Parkinson's and Alzheimer's disease. Both of these conditions are characterised by a build-up of incorrectly folded, aggregated and ultimately neurotoxic proteins.

Under the terms of the agreement, AstraZeneca will make specified upfront and milestone payments and will assume all of the programme's research and development activities. The financial terms of the deal have not been disclosed.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Mergers and Acquisitions

Add Your Comment